Member Info for Saint68

Don’t care

I am but I know this board frowns on chat about other companies so I’ll only do a quick brief and then let it be.

Commercialising is a difficult one as it depends on whether they get fast track designation. The CEO has hinted at this but nothing concrete yet.

Licensing will only happen once the trials have been concluded but in my opinion we won’t be the ones licensing as we’ll get bought out before that happens.

The CEO has recently hinted at partnerships and that this could happen pretty soon.

It’s my biggest holding and the potential there, in my opinion , is higher than here as they will be able to treat around 85% of all solid tumours. Their 2nd trial started recently and preclinical data was compared to Pfizer’s blockbuster drug Enhertu. The results blew it out of the water. Enhertu generates sales of around $5 billion per annum.

Hopefully both companies start to realise their true value soon.

Buying back in suggests you were completely out. Adding to your investment would be buying more or topping up.

How can your average be £6.89 when you bought back in at £8 and it hasn’t been under £7 in months ? I smell bullsh4t.

Jezza - “ Is there anything we can click to stop pumpky posting?l - yes, the filter button. They on,y post because numpties keep on replying to their drivel.

Https://avacta.wistia.com/medias/xktyxrb2wy

Cyrox - I will counter your “ Continued silence may well see this in the 7s” with - one bit of good news will see this back over £17 very quickly. It will take stellar news to get back over the all time high of £60 though.

Spot on Jam. The posters who reply to the twats are as big a problem as them. Some people never learn. I’m now binning the repliers as I have no time or desire to read the constant bickering.

Forgot to add that you've already missed out at anywhere near the £3.50 figure.

Read all the equity raising RNS's. All have included warrants at varying costs.

Now on the website : https://avacta.com/investors/publications/

Charting on AIM or early biotech a mugs game as it’s mostly sentiment driven. Plenty of charlatans out there will try to convince you otherwise but fail to mention any of their losses.

Rubbish in, rubbish out springs to mind.

Great post MrsI. I agree that market sensitive info should be released via RNS as soon as possible.

JHFH - I don’t think the patients would be able to divulge any info as they would probably be under NDA. They would need clearance from MDA / HEMO first.

What other companies have a pipeline like ours and at what stage are they in development ?

It is Jezza as is yours about Vlad not being desperate to impress big pharma. Before your time on the board the last time he promised non dilutive funding, he went and did a large placing at a big discount. He’s a very stubborn person and is sometimes his own worst enemy.

But he should be trying to impress people Jezza. At the moment we’re relying on private investors to keep the company going.

I disagree B2 , I think we are pretty close to a deal AVA6000. Other deals to materialise later this year and next year.

If his negotiating is anything like his presentations we’ll have no chance of selling for billions. We have the science but we need the complete package for a successful sale / jv. Hopefully a jv will result in the company being in a position to employ a decent PR person.

Doubt it. Been here years and he’s yet to give a decent interview. Comms are appalling.